scispace - formally typeset
Open AccessJournal ArticleDOI

Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance

Reads0
Chats0
TLDR
This AASLD 2018 Hepatitis B Guidance provides a data-supported approach to screening, prevention, diagnosis, and clinical management of patients with hepatitis B.
About
This article is published in Hepatology.The article was published on 2018-04-01 and is currently open access. It has received 2399 citations till now. The article focuses on the topics: Hepatitis B & Mass screening.

read more

Citations
More filters
Journal ArticleDOI

Toward a complete cure for chronic hepatitis B: Novel therapeutic targets for hepatitis B virus

TL;DR: In this article , the authors summarized the current knowledge about novel treatments and combination treatments for a complete hepatitis B virus cure, defined by either the loss of hepatitis B surface antigen, undetectable serum HBV DNA levels, and/or seroconversion to hepatitis b surface antibody.
Journal ArticleDOI

Monotherapy with tenofovir disoproxil fumarate for adefovir-resistant vs. entecavir-resistant chronic hepatitis B: A 5-year clinical trial.

TL;DR: Up to 240 weeks of TDF monotherapy provided an increasing virologic response rate in heavily pretreated patients with HBV resistant to ETV and/or ADV, however, it was associated with poor serological responses and decreasing renal function and bone mineral density.
Journal ArticleDOI

Cost-effectiveness of antiviral treatment in adult patients with immune-tolerant phase chronic hepatitis B.

TL;DR: Starting antiviral therapy in IT phase is cost-effective compared with delaying the treatment until the active hepatitis phase in CHB patients, especially with increasing HCC risk, decreasing drug costs and consideration of productivity loss.
References
More filters
Journal ArticleDOI

Management of hepatocellular carcinoma.

TL;DR: The prevention of Cirrhosis can prevent the development of HCC and progression from chronic HCV infection to advanced fibrosis or cirrhosis may be prevented in 40% of patients who are sustained responders to new antiviral strategies, such as pegylated interferon and ribavirin.
Journal ArticleDOI

AASLD guidelines for the treatment of hepatocellular carcinoma

TL;DR: This paper aims to demonstrate the efforts towards in-situ applicability of EMMARM, as to provide real-time information about concrete mechanical properties such as E-modulus and compressive strength.
Journal ArticleDOI

Chronic hepatitis B: Update 2009

TL;DR: The 2009 update of the American Association for the Study of Liver Diseases (AASLD) Practice Guidelines for Management of Chronic Hepatitis B is now posted online at www.aasld.org, and the recommendation for first-line oral antiviral medications has been changed to tenofovir or entecavir, and adefovir has been moved to second-line Oral antiviral medication.
Journal ArticleDOI

Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures

TL;DR: More efficacious treatments, mass immunization programs, and safe injection techniques are essential for eliminating HBV infection and reducing global HBV‐related morbidity and mortality.
Related Papers (5)

Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study

Devin Razavi-Shearer, +195 more